DB06544ExperimentalGene Therapies
MG98, a second-generation antisense oligodeoxynucleotide inhibitor of human DNMT1, was investigated in the completed clinical trial NCT00003890 for treating patients with advanced solid tumors.
- Primary indication
- Investigated for use/treatment in head and neck cancer, renal cell carcinoma, myelodysplastic syndrome, and leukemia (myeloid).Curator reviewed
Resolves to
Targets
What you can answer from here — as of April 02, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with MG98, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account